Malignant pleural mesothelioma

Current Treatment Options in Oncology

Volumn 1, Issue 4, 2000, Pages 313-326

  Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Clin Oncol; Gemcitabine; Main Drug Interaction; Malignant Pleural Mesothelioma; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER STAGING; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PLEURA TUMOR; PROGNOSIS; RADIOTHERAPY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; NEOPLASM STAGING; PALLIATIVE CARE; PLEURAL NEOPLASMS; PROGNOSIS; RADIOTHERAPY;

EID: 0034309192     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-000-0047-4     Document Type: Article

References (45)

1. Kindler HL, Vogelzang NJ: Mesothelioma. In Oncologic Therapies. Edited by Vokes EE, Golomb HM. Berlin: Springer-Verlag; 1999:635–651.
2. Baas P, Schouwink H, Zoetmulder FAN: Malignant pleural mesothelioma. Ann Oncol 1998, 9:139–149. An excellent overview of malignant pleural mesothelioma. DOI: 10.1023/A:1008239116237
3. Boutin C, Rey F: Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993, 72:389–393. DOI: 10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
4. International Mesothelioma Interest Group: A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108:1122–1128. The new IMIG staging system for mesothelioma.
5. Boutin C, Rey F, Gouvernet J, et al.: Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993, 72:394–404. DOI: 10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
6. Sugarbaker DJ, Strauss GM, Lynch TJ, et al.: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993, 11:1172–1178.
7. Herndon JE II, Green MR, Chahinian AP, et al.: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723–731.
8. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996, 14:1007–1017. A comprehensive review of chemotherapy for malignant mesothelioma.
9. Middleton GW, Smith IE, O’Brien ME, et al.: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998, 9:269–273. The authors describe a phase II trial in which 62% of patients obtained an improvement in their symptoms with chemotherapy despite an objective response rate of only 20%. DOI: 10.1023/A:1008236010868
10. Steele JPC, Evans MT, Tischkowitz MD, et al.: Vinorelbine is an active and well tolerated drug for the treatment of malignant mesothelioma: a phase II study. Proc Am Soc Clin Oncol 1999, 18:490a.
11. Byrne MJ, Davidson JA, Musk AW, et al.: Cisplatin and gemcitabine for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25–30. A report on one of the most active regimens for this disease.
12. Lerner HJ, Schoenfeld DA, Martin A, et al.: Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981–1985. DOI: 10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
13. Solheim OP, Saeter G, Finnanger AM, et al.: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992, 65:956–960.
14. Thodtmann R, Depenbrock H, Dumez H, et al.: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999, 17:3009–3016. The authors describe a phase I trial in which 38% of patients with malignant mesothelioma achieved an objective response.
15. Calvert AH, Hughes AN, Calvert PM, et al.: Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Proc Am Soc Clin Oncol 2000, 19:495a.
16. Fizazi K, Ducreux M, Ruffie P, et al.: Phase I, dose-finding and pharmacologic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000, 18:2293–2300.
17. Fizazi H, Doubre H, Viala J, et al.: The combination of raltitrexed (’tomudex’) and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. Proc Am Soc Clin Oncol 2000, 19:578a.
18. Kindler HL, Millard F, Herndon JE, et al.: Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer, in press.
19. van Meerbeeck JP, Baas P, Debruyne C, et al.: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999, 85:2577–2582. DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
20. Bischoff HG, Manegold C, Knopp M, et al.: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1998, 17:464a.
21. Aversa SML, Favaretto AG: Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999, 1:1. DOI: 10.3816/CLC.1999.n.006
22. van Meerbeeck J, Debruyne C, vanZandwijk N, et al.: Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996, 74:961–963.
23. Vogelzang NJ, Herndon JE, Miller A, et al.: High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999, 10:597–600. DOI: 10.1023/A:1026438215309
24. Maksymiuk AW, Jung S-H, Marschke RF, et al.: Phase II trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 1995, 14:435.
25. Nakano T, Chahinian AP, Shinjo M, et al.: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II trial and pharmacokinetic profile. Cancer 1999, 85:2375–2384. DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E
26. Kindler HL, Herndon JE, Vogelzang NJ, et al.: CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Am Soc Clin Oncol 2000, 19:505a.
27. Belani CP, Adak S, Aisner S, et al.: Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999, 18:474a.
28. Vorobiof DA, Chasen MR, Abratt RP, et al.: Phase II trial of single agent taxotere (T) in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2000, 19:578a.
29. Boutin C, Rey F, Viallat J-R, et al.: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995, 108:754–758.
30. Rusch VW, Rosenzweig K, Venkatraman ES, et al.: A prospective trial of surgical resection and high dose hemithoracic radiation for malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2000, 19:578a.
31. Sugarbaker D.J, Norberto JJ: Multimodality management of malignant pleural mesothelioma. Chest 1998, 113:61S-65S.
32. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996, 111:815–826. DOI: 10.1016/S0022-5223(96)70342-2
33. Perez-Soler R, Walsh GL, Swisher SG, et al.: Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1999, 18:421a.
34. Taub RN, Keohan ML, Vogelzang NJ, et al.: Phase II trial of Onconase (Ò) in patients (PTS) with advanced malignant mesothelioma (MM): analysis of survival. Proc Am Soc Clin Oncol 1999, 18:524a.
35. Vogelzang N, Taub R, Shin D, et al.: Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (PTS) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc Am Soc Clin Oncol 2000, 19:505a.
36. Ohta Y, Shridhar V, Bright RK, et al.: VEGF, VEGF Type C, and their receptors play an important role in angiogenesis and lymphangiogensis in human malignant mesothelioma tumors. Br J Cancer 1999, 81:54–61. DOI: 10.1038/sj.bjc.6690650
37. Kumar-Singh S, Vermeulen PB, Weyler J, et al.: Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma J Pathol 1997, 182:211–216. DOI: 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
38. Treat J, Kaiser L, Recio A, et al.: Adenoviral-mediated intrapleural HSVtk gene therapy (AdRSVtk) for malignant mesothelioma: a phase I clinical trial. Proc Am Soc Clin Oncol 1997, 16:433a.
39. Pass HI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628–633. DOI: 10.1007/BF02303746
40. Carbone M, Pass HI, Rizzo P, et al.: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994, 9:1781–1790.
41. Xie YC, Hwang C, Overwijk W, et al.: Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst 1999, 91:169–175. DOI: 10.1093/jnci/91.2.169
42. Raghavan D, Gianoutsos P, Bishop J, et al.: Phase II trial of carboplatin in the management of mesothelioma. J Clin Oncol 1990, 8:151–154.
43. Zidar BL, Green S, Pierce HI, et al.: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988, 6:223–226. DOI: 10.1007/BF00175403
44. Bajorin D, Kelsen D, Mintzer DM: Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987, 71:857–858.
45. Chahinian AP, Antman K, Goutsou M, et al.: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993, 8:1559–1565.